Muscle Spasticity Market, By Drug Type, By Route of Administration, By Distribution Channel, By Geography

PUBLISHED: June 23, 2026

PAGES: 256 Pages

DELIVERY TIME: 2-3 business days

ADD TO COMPARE

SELECT AN OPTION

Description

Muscle Spasticity Market is estimated to be valued at USD 11.4 Bn in 2026 and is expected to reach USD 23.7 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8.9% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 11.4 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	8.90%	2033 Value Projection:	USD 23.7 Bn

When muscles become stiff or contract, the condition is called as muscle spasticity. Muscle spasticity is seen in a variety of conditions such as spinal cord injury, brain injury, diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). It occurs when the nerve impulses involved in controlling muscle movement are either damaged or interrupted. Muscle spasticity can cause a difficulty in talking, moving, or stretching.

Symptoms of muscle spasticity include increased muscle tone, involuntary movements, abnormal posture, pain or discomfort, bone and joint deformities, decreased ability to function, and others. Spasticity should be treated when it causes pain, interferes with daily activities or sleep, or leads to decreased ability to function. Treatment given is based on the patient's needs, preferences, and goals. The treatment includes physical therapy, occupational therapy, casting or bracing, and oral medications. Surgery may also be needed in certain cases. Oral medications are only used when the symptoms interfere with daily activities or sleep. Common medications include baclofen, dantrolene sodium, botulinum toxin, diazepam, and others.

Market Dynamics

The increasing launches of new drugs and regulatory approvals for muscle spasticity are expected to drive the market growth during the forecast period. For instance, in July 2021, Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, and Teijin Pharma Limited, the core company of the Teijin Group's healthcare business, jointly announced that Teijin Pharma was granted additional approval by Japan's Ministry of Health, Labor and Welfare (MHLW) to market Xeomin (incobotulinumtoxinA), a neurotoxin treatment for intramuscular injection in 50, 100 or 200 units for the treatment of lower limb spasticity.

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global muscle spasticity market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Ipsen Pharma, Allergan, Acorda Therapeutics, Inc., Merz Pharma, Teva Pharmaceutical Industries Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Beximco Pharmaceuticals Ltd., Johnson & Johnson Private Limited, Zydus Cadila, F. Hoffmann-La Roche Ltd., and Elite Pharmaceuticals Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global muscle spasticity market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global muscle spasticity market

Market Segmentation

By Drug Type (Revenue, USD Bn, 2021-2033)
Baclofen
Botulinum Toxin
Diazepam
Tizanidine
Dantrolene Sodium
Others
By Route of Administration (Revenue, USD Bn, 2021-2033)
Oral
Intramuscular
Others
By Distribution Channel (Revenue, USD Bn, 2021-2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region (Revenue, USD Bn, 2021-2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC
- Israel
- Rest of Middle East
Africa
- South Africa
- Central Africa
- North Africa
Key Players
Ipsen Pharma
Allergan
Acorda Therapeutics, Inc.
Merz Pharma
Teva Pharmaceutical Industries Ltd.
Novartis AG
Sun Pharmaceutical Industries Ltd.
Beximco Pharmaceuticals Ltd.
Johnson & Johnson Private Limited
Zydus Cadila
Hoffmann-La Roche Ltd.
Elite Pharmaceuticals Inc.

Product Code: CMI4827

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunity
Impact Analysis
Key Highlights
Pipeline Analysis
Regulatory Scenario
Product Launches / Approvals
PEST Analysis
PORTER's Analysis
Merger, Collaboration and Acquisitions Scenario

4. Global Muscle Spasticity Market, By Drug Type, 2021-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Baclofen
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Botulinum Toxin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Diazepam
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Tizanidine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Dantrolene Sodium
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

5. Global Muscle Spasticity Market, By Route of Administration, 2021-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Intramuscular
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

6. Global Muscle Spasticity Market, By Distribution Channel, 2021-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

7. Global Muscle Spasticity Market, By Region, 2021-2033, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033, (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033, (USD Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033, (USD Bn)
  - U.K.
  - Germany
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033, (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033, (USD Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Region/Countries, 2021-2033, (USD Bn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Heat Map Analysis
Market Share Analysis
- Ipsen Pharma
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Allergan
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Acorda Therapeutics, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Merz Pharma
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Teva Pharmaceutical Industries Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Novartis AG
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Sun Pharmaceutical Industries Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Beximco Pharmaceuticals Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Johnson & Johnson Private Limited
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Zydus Cadila
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Hoffmann-La Roche Ltd
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Elite Pharmaceuticals Inc
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
  - Analyst Views